EurekAlert! -
28 Aug 2017 06:00
(European Society of Cardiology) Inclisiran lowers low-density lipoprotein (LDL; 'bad') cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol, according to late-breaking results from the ORION 1 trial presented today in a Hot Line LBCT Session at ESC Congress.
Share this Article